ArriVent BioPharma (AVBP) News Today $27.41 -0.01 (-0.04%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ArriVent BioPharma Advances Cancer Therapeutics PipelineNovember 19 at 7:37 AM | markets.businessinsider.comArriVent BioPharma Reports Advancements and Q3 2024 Financial ResultsNovember 16, 2024 | msn.comArriVent BioPharma, Inc.: Promising Clinical Trials and Strategic Collaborations Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comArriVent BioPharma, Inc. Buy Rating: Strong Financials, Clinical Progress, and Promising Catalysts Support Upside PotentialNovember 16, 2024 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) Announces Third Quarter 2024 Financial ResultsNovember 16, 2024 | americanbankingnews.comArriVent BioPharma's (AVBP) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of ArriVent BioPharma in a research note on Friday.November 15, 2024 | marketbeat.comArriVent BioPharma Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comDiscover the 3 Best-Performing Biotech IPO Stocks of 2024 (AVBP)Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.November 6, 2024 | marketbeat.comAlphaCentric Advisors LLC Sells 71,000 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)AlphaCentric Advisors LLC trimmed its position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 82.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,000 shares of the company's stock after selliNovember 5, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Hits New 1-Year High - Should You Buy?ArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week High - Still a Buy?October 24, 2024 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest UpdateArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 3,350,000 shares, a growth of 80.1% from the September 15th total of 1,860,000 shares. Currently, 17.3% of the shares of the company are short sold. Based on an average daily trading volume, of 249,500 shares, the days-to-cover ratio is presently 13.4 days.October 12, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Up 6.3%ArriVent BioPharma (NASDAQ:AVBP) Trading 6.3% HigherOctober 3, 2024 | marketbeat.comNovo Holdings A S Raises Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Novo Holdings A S boosted its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 39.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,500,000 shares of the company's stock after purchasing an additional 422,860September 30, 2024 | marketbeat.comShort Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Rises By 13.4%ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totalling 1,860,000 shares, an increase of 13.4% from the August 31st total of 1,640,000 shares. Approximately 9.6% of the company's stock are sold short. Based on an average trading volume of 234,300 shares, the short-interest ratio is presently 7.9 days.September 29, 2024 | marketbeat.comBuy Rating for ArriVent BioPharma Backed by Firmonernib’s Efficacy in NSCLC TrialsSeptember 24, 2024 | markets.businessinsider.comBiocureTechInc (CURE-X.CN)September 20, 2024 | finance.yahoo.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $23.94ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $23.94September 18, 2024 | marketbeat.comArriVent BioPharma: Bringing A Novel Cancer Drug From ChinaSeptember 18, 2024 | seekingalpha.comAnalyst boosts ArriVent BioPharma shares price target after promising trial dataSeptember 12, 2024 | uk.investing.comArriVent BioPharma stock target raised on positive trial resultsSeptember 12, 2024 | investing.comArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3% ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3%September 11, 2024 | marketbeat.comArriVent BioPharma, Inc.: Strong Clinical Data and Improved Financial Outlook Prompt Buy Rating and Price Target IncreaseSeptember 11, 2024 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) PT Raised to $36.00 at CitigroupCitigroup boosted their price target on ArriVent BioPharma from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday.September 11, 2024 | marketbeat.comArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLCSeptember 11, 2024 | msn.comBuy Rating Affirmed for ArriVent BioPharma on Firmonertinib’s Promising Study Results and Market PotentialSeptember 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for ArriVent BioPharma Amid Promising Firmonertinib Trial ResultsSeptember 11, 2024 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) Receives Outperform Rating from OppenheimerOppenheimer reaffirmed an "outperform" rating and set a $39.00 price objective (up from $35.00) on shares of ArriVent BioPharma in a research note on Tuesday.September 10, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up After Analyst UpgradeArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst UpgradeSeptember 10, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $38.00 at The Goldman Sachs GroupThe Goldman Sachs Group upped their price target on ArriVent BioPharma from $28.00 to $38.00 and gave the stock a "buy" rating in a research note on Tuesday.September 10, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume IncreaseArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading VolumeSeptember 9, 2024 | marketbeat.comArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung CancerSeptember 9, 2024 | globenewswire.comWe're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn RateSeptember 6, 2024 | finance.yahoo.comArriVent BioPharma (NASDAQ:AVBP) Trading 3.2% Higher ArriVent BioPharma (NASDAQ:AVBP) Trading 3.2% HigherSeptember 6, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Trading Up 2.4%ArriVent BioPharma (NASDAQ:AVBP) Trading 2.4% HigherAugust 28, 2024 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week High at $26.24ArriVent BioPharma (NASDAQ:AVBP) Sets New 52-Week High at $26.24August 26, 2024 | marketbeat.comArriVent BioPharma’s Firmonertinib: A Promising Treatment for EGFR PACC Mutations in NSCLCAugust 26, 2024 | markets.businessinsider.comHere's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price StrengthAugust 19, 2024 | msn.comBuy Rating Affirmed for ArriVent BioPharma on Strong Clinical Prospects and Financial StabilityAugust 16, 2024 | markets.businessinsider.comHC Wainwright Boosts ArriVent BioPharma (NASDAQ:AVBP) Price Target to $30.00HC Wainwright lifted their price target on shares of ArriVent BioPharma from $25.00 to $30.00 and gave the company a "buy" rating in a report on Friday.August 16, 2024 | marketbeat.comArriVent BioPharma Reports Strong Second Quarter and Highlights ProgressAugust 16, 2024 | msn.comBuy Rating Affirmed on ArriVent BioPharma’s Strong Clinical Developments and Strategic PartnershipsAugust 16, 2024 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) Announces Earnings ResultsArriVent BioPharma (NASDAQ:AVBP - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.65) EPS for the quarter, meeting analysts' consensus estimates of ($0.65).August 15, 2024 | marketbeat.comOppenheimer Reaffirms "Outperform" Rating for ArriVent BioPharma (NASDAQ:AVBP)Oppenheimer reissued an "outperform" rating and issued a $35.00 target price on shares of ArriVent BioPharma in a research note on Thursday.August 15, 2024 | marketbeat.comArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2024 Financial ResultsAugust 15, 2024 | finanznachrichten.deAarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharmaAugust 15, 2024 | businesswire.comArriVent BioPharma Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | globenewswire.comArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung CancerAugust 14, 2024 | msn.com648,735 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Vanguard Group Inc.Vanguard Group Inc. purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 648,735 shares of the company's stock, valued at approAugust 14, 2024 | marketbeat.comArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung CancerAugust 12, 2024 | globenewswire.comArriVent BioPharma, Inc. (NASDAQ:AVBP) institutional investors have had a good week as stock gains 19%July 27, 2024 | finance.yahoo.com Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! AVBP Media Mentions By Week AVBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVBP News Sentiment▼0.540.46▲Average Medical News Sentiment AVBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVBP Articles This Week▼92▲AVBP Articles Average Week Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rhythm Pharmaceuticals News Today Apellis Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Agios Pharmaceuticals News Today Verona Pharma News Today PTC Therapeutics News Today Dyne Therapeutics News Today Bausch Health Companies News Today Edgewise Therapeutics News Today Merus News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVBP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVBP Stock Alerts